Spero Therapeutics (SPRO.US): The 2024 Q1 financial report achieved revenue of $9.267 million, previous value of USD 2.069 million, expected value of USD 21.53 million; earnings per share were -0.24 USD, previous value of -0.25 USD, and expected value of -0.04 USD.
Spero Therapeutics(SPRO.US)：2024年Q1财报实现营收926.7万美元，前值为206.9万美元，预期值为2153万美元；每股收益为-0.24美元，前值为-0.25美元，预期值为-0.04美元。
Spero Therapeutics (SPRO.US): The 2024 Q1 financial report achieved revenue of $9.267 million, previous value of USD 2.069 million, expected value of USD 21.53 million; earnings per share were -0.24 USD, previous value of -0.25 USD, and expected value of
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.